9 years ago

Oxford BioTherapeutics Secures $10m Loan for Cancer Therapy Pipeline

  • Oxford BioTherapeutics receives a $10m senior secured term loan from Oxford Finance to progress its pipeline of novel immuno-oncology and antibody drug conjugate programs.

      • ProblemHealthcare

      "developing antibody-based therapies to treat cancer"

      Solution

      "combining immuno-oncology, Antibody-Drug Conjugate and human monoclonal antibody approaches against novel human tumor cell membrane, derived checkpoint targets"

      Covered on